Department of Pediatrics, Institute of Medical Sciences, Medical College of Rzeszów University, Rzeszów, Poland.
Department of Biochemistry and General Chemistry, Institute of Medical Sciences, Medical College of Rzeszów University, Rzeszów, Poland.
Front Endocrinol (Lausanne). 2023 Aug 21;14:1235409. doi: 10.3389/fendo.2023.1235409. eCollection 2023.
The purpose of our study was tomeasure the level of leptin and biologically active leptin (bioLEP) in children with type 1 diabetes, depending on the duration of diabetes and its degree of metabolic control.
The study included 94 children (58 boys and 36 girls). In a group of children with diabetes, 40 patients were newly diagnosed with type 1 diabetes, 40 children who have diabetes for more than a year (20 with good metabolic control and 20 with poor metabolic control). The control group consisted of 14 healthy children. The serum level of leptin and bioLEP was measured using a sandwich enzyme-linked immunosorbent assay. To our knowledge, this is the first study to describe bioLEP levels among diabetic children with different forms of disease control.
Lower levels of leptin were found in children with diabetes compared to healthy children. Furthermore, we found a statistically higher concentration of leptin in the group of children with newly diagnosed diabetes compared to children from the diabetic group with poor metabolic control and lower than healthy children (11.19 vs. 7.84 and 20.94 ng/mL). Moreover, children in the metabolically well-controlled group had statistically lower levels of this hormone (5.11 ng/mL) than healthy children. Leptin concentrations differed significantly between underweight, overweight, and obese children.
In our study, the level of bioLEP differed significantly between children in the newly diagnosed diabetes group and children in the long-term, poorly controlled diabetes group and healthy controls. Despite many studies published in recent years, many aspects of leptin secretion, action, and mechanisms of its influence on carbohydrate and fat metabolism are still to be clarified. In our opinion, studies evaluating the status of bioLEP in diabetes can also contribute to a better understanding of the mechanisms regulating metabolism.
我们的研究目的是测量 1 型糖尿病患儿瘦素和生物活性瘦素（bioLEP）的水平，这取决于糖尿病的病程和代谢控制程度。
研究纳入 94 名儿童（58 名男孩和 36 名女孩）。在糖尿病患儿组中，40 例为新诊断的 1 型糖尿病患儿，40 例糖尿病病程超过 1 年（20 例代谢控制良好，20 例代谢控制不佳）。对照组由 14 名健康儿童组成。采用夹心酶联免疫吸附试验法测定血清瘦素和 bioLEP 水平。据我们所知，这是首次描述不同疾病控制形式的糖尿病患儿 bioLEP 水平的研究。
与健康儿童相比，糖尿病患儿的瘦素水平较低。此外，我们发现新诊断的糖尿病患儿组的瘦素浓度明显高于代谢控制不佳的糖尿病患儿组和健康儿童组（11.19 比 7.84 和 20.94ng/ml）。此外，代谢控制良好的患儿组的这种激素水平明显低于健康儿童（5.11ng/ml）。瘦素浓度在体重不足、超重和肥胖儿童之间有显著差异。
在我们的研究中，新诊断糖尿病组和长期代谢控制不佳糖尿病组的儿童与健康对照组的 bioLEP 水平有显著差异。尽管近年来发表了许多研究，但瘦素分泌、作用及其影响碳水化合物和脂肪代谢的机制的许多方面仍有待阐明。在我们看来，评估糖尿病患者 bioLEP 状况的研究也有助于更好地了解调节代谢的机制。
